drugset
drugset / Trial / NCT05953610

Endotypic Traits and Obstructive Sleep Apnea Surgery

NCT05953610 ↗

Phase 2 Recruiting 150 enrolled University of California, Los Angeles National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).

Timeline

Start
2024-01-07
Primary completion
2028-08-31
Completion
2028-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetazolamide Small molecule 500 mg —
Subject Eszopiclone Small molecule 3 mg —

Indications

obstructive sleep apnea syndrome